Authors' Reply

Affiliations

¹ Department of Nephrology, Showa University School of Medicine, Tokyo, Japan.
² Department of Data Science, Yokohama City University, Yokohama, Japan.
³ Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁴ Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁵ Development Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands.

Comment

Tadao Akizawa et al. J Am Soc Nephrol. 2021 Apr.

. 2021 Apr;32(4):1005-1007.

doi: 10.1681/ASN.2021010051. Epub 2021 Mar 1.

¹ Department of Nephrology, Showa University School of Medicine, Tokyo, Japan.
² Department of Data Science, Yokohama City University, Yokohama, Japan.
³ Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁴ Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁵ Development Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands.

No abstract available

Keywords: chronic kidney disease; erythropoiesis-stimulating agent; hemodialysis; hypoxia-inducible factor; randomized controlled trial.

Comment in

Roxadustat for Renal Anemia in ESRD from PKD Patients: Is It Safe Enough?
Liu F, Wang J, Ye Q, Fu H, Mao J. Liu F, et al. J Am Soc Nephrol. 2021 Apr;32(4):1005. doi: 10.1681/ASN.2020111664. Epub 2021 Mar 1. J Am Soc Nephrol. 2021. PMID: 33649100 Free PMC article. No abstract available.

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Akizawa T, et al. J Am Soc Nephrol. 2020 Jul;31(7):1628-1639. doi: 10.1681/ASN.2019060623. Epub 2020 Jun 3. J Am Soc Nephrol. 2020. PMID: 32493693 Free PMC article. Clinical Trial.

1. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M: Phase 3, randomized, double-blind, active-comparator (darbepoetin Alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol 31: 1628–1639, 2020 - PMC - PubMed
1. Liu F, Wang J, Ye Q, Fu H, Mao J: Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough? J Am Soc Nephrol 32: 1005, 2021 - PMC - PubMed
1. Buchholz B, Eckardt KU: Role of oxygen and the HIF-pathway in polycystic kidney disease. Cell Signal 69: 109524, 2020 - PubMed
1. Kraus A, Peters DJM, Klanke B, Weidemann A, Willam C, Schley G, et al. .: HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int 94: 887–899, 2018 - PubMed
1. Shutov E, Sułowicz W, Esposito C, et al. .: Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 2021, in press - PMC - PubMed